Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Breast Cancer

Free Subscription 05.07.2021 1 Am J Clin Oncol 4 Ann Surg Oncol 5 BMC Cancer 1 Breast Cancer 1 Breast Cancer (Auckl) 1 Breast Cancer Res 23 Breast Cancer Res Treat 1 Breast J 2 Cancer Epidemiol Biomarkers Prev 3 Cancer Res 3 Carcinogenesis 1 Clin Cancer Res 1 Clin Exp Metastasis 2 Eur J Cancer 1 Eur J Surg Oncol 1 Gene 2 Int J Cancer 5 Int J Radiat Oncol Biol Phys 1 J Clin Oncol 4 NPJ Breast Cancer 1 Oncogene 1 PLoS Comput Biol 1 Radiology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Oncol

1. SPANHEIMER PM, Bashir A, Lorenzen AW, Beck AC, et al
   A Pilot Study of Preoperative Vandetanib on Markers of Proliferation and Apoptosis in Breast Cancer.
   Am J Clin Oncol. 2021 Jun 30. pii: 00000421-900000000-98548.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

2. FURLAN C, Matheus CN, Jales RM, Derchain SFM, et al
   ASO Author Reflections: A Roadmap to Early Detection of Patients at Increased Risk of Developing Persistent Lymphedema After Breast Cancer Surgery Has Been Outlined: What to Offer Them Remains Elusive.
   Ann Surg Oncol. 2021 Jun 27. pii: 10.1245/s10434-021-10360.
   PubMed        
   
   
3. SAUDER CAM, Li Q, Bold RJ, Ruddy KJ, et al
   Secondary Breast Cancer Sociodemographic Characteristics and Survival by Age Group.
   Ann Surg Oncol. 2021 Jun 29. pii: 10.1245/s10434-021-10340.
   PubMed         Abstract available
   
   
4. GOLDBACH MM, Burkbauer L, Bharani T, Williams AD, et al
   ASO Visual Abstract: Effectiveness of a Short Duration of Neoadjuvant Endocrine Therapy in Patients with HR+ Breast Cancer-An NCDB Analysis (2004-2016).
   Ann Surg Oncol. 2021 Jun 28. pii: 10.1245/s10434-021-10353.
   PubMed        
   
   
5. KOUWENBERG CAE, Kranenburg LW, Busschbach JJ, Mureau MAM, et al
   Why Breast-Conserving Therapy Should be Considered Treatment of Choice in Early-Stage Breast Cancer Patients.
   Ann Surg Oncol. 2021 Jun 26. pii: 10.1245/s10434-021-10203.
   PubMed        
   
   

   
   BMC Cancer

6. JIAO X, Wang B, Feng C, Song S, et al
   Formin-like protein 2 promotes cell proliferation by a p27-related mechanism in human breast cancer cells.
   BMC Cancer. 2021;21:760.
   PubMed         Abstract available
   
   
7. ZHAO Q, Hughes R, Neupane B, Mickle K, et al
   Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer.
   BMC Cancer. 2021;21:758.
   PubMed         Abstract available
   
   
8. WANG K, Jin X, Wang W, Yu X, et al
   The role of postmastectomy radiation in patients with ypN0 breast cancer after neoadjuvant chemotherapy: a meta-analysis.
   BMC Cancer. 2021;21:728.
   PubMed         Abstract available
   
   
9. GAO J, Wang S, Zhang Z, Li J, et al
   Long non-coding RNA BRE-AS1 inhibits the proliferation, migration, and invasion of cancer cells in triple-negative breast cancer and predicts patients' survival by downregulating miR-21.
   BMC Cancer. 2021;21:745.
   PubMed         Abstract available
   
   
10. HE C, Zhu WX, Tang Y, Bai Y, et al
    Knowledge of a cancer diagnosis is a protective factor for the survival of patients with breast cancer: a retrospective cohort study.
    BMC Cancer. 2021;21:739.
    PubMed         Abstract available
    
    

    
    Breast Cancer

11. AMIOKA A, Kadoya T, Sueoka S, Kobayashi Y, et al
    Correction to: Effect of Wnt5a on drug resistance in estrogen receptorpositive breast cancer.
    Breast Cancer. 2021 Jun 28. pii: 10.1007/s12282-021-01268.
    PubMed        
    
    

    
    Breast Cancer (Auckl)

12. DAVEY MG, Ryan EJ, Burke D, McKevitt K, et al
    Evaluating the Clinical Utility of Routine Sentinel Lymph Node Biopsy and the Value of Adjuvant Chemotherapy in Elderly Patients Diagnosed With Oestrogen Receptor Positive, Clinically Node Negative Breast Cancer.
    Breast Cancer (Auckl). 2021;15:11782234211022203.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

13. SAYED S, Fan S, Moloo Z, Wasike R, et al
    Breast cancer risk factors in relation to molecular subtypes in breast cancer patients from Kenya.
    Breast Cancer Res. 2021;23:68.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

14. AL-KAWAZ A, Miligy IM, Toss MS, Mohammed OJ, et al
    The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ.
    Breast Cancer Res Treat. 2021;188:53-63.
    PubMed         Abstract available
    
    
15. DEMPSEY N, Rosenthal A, Dabas N, Kropotova Y, et al
    Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies.
    Breast Cancer Res Treat. 2021;188:21-36.
    PubMed         Abstract available
    
    
16. SUNDARESAN TK, Dubash TD, Zheng Z, Bardia A, et al
    Evaluation of endocrine resistance using ESR1 genotyping of circulating tumor cells and plasma DNA.
    Breast Cancer Res Treat. 2021;188:43-52.
    PubMed         Abstract available
    
    
17. BOYER JZ, Phillips GDL, Nitta H, Garsha K, et al
    Activity of trastuzumab emtansine (T-DM1) in 3D cell culture.
    Breast Cancer Res Treat. 2021;188:65-75.
    PubMed         Abstract available
    
    
18. MATOSSIAN MD, Elliott S, Van Hoang T, Burks HE, et al
    NEK5 activity regulates the mesenchymal and migratory phenotype in breast cancer cells.
    Breast Cancer Res Treat. 2021 Jul 1. pii: 10.1007/s10549-021-06295.
    PubMed         Abstract available
    
    
19. AROLE V, Nitta H, Wei L, Shen T, et al
    M2 tumor-associated macrophages play important role in predicting response to neoadjuvant chemotherapy in triple-negative breast carcinoma.
    Breast Cancer Res Treat. 2021;188:37-42.
    PubMed         Abstract available
    
    
20. RAKOVITCH E, Parpia S, Koch A, Grimard L, et al
    DUCHESS: an evaluation of the ductal carcinoma in situ score for decisions on radiotherapy in patients with low/intermediate-risk DCIS.
    Breast Cancer Res Treat. 2021;188:133-139.
    PubMed         Abstract available
    
    
21. HABIBI M, Prasath V, Dembinski R, Sacks JM, et al
    Comparison of mastectomy and breast reconstruction outcomes using low thermal dissection versus traditional electrocautery: a blinded randomized trial.
    Breast Cancer Res Treat. 2021;188:101-106.
    PubMed         Abstract available
    
    
22. LERTWILAIWITTAYA P, Roothumnong E, Nakthong P, Dungort P, et al
    Thai patients who fulfilled NCCN criteria for breast/ovarian cancer genetic assessment demonstrated high prevalence of germline mutations in cancer susceptibility genes: implication to Asian population testing.
    Breast Cancer Res Treat. 2021;188:237-248.
    PubMed         Abstract available
    
    
23. HAN X, Duan X, Liu Z, Long Y, et al
    ZEB1 directly inhibits GPX4 transcription contributing to ROS accumulation in breast cancer cells.
    Breast Cancer Res Treat. 2021 Jun 24. pii: 10.1007/s10549-021-06301.
    PubMed         Abstract available
    
    
24. KEARNEY M, Franks L, Lee S, Tiersten A, et al
    Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer.
    Breast Cancer Res Treat. 2021 Jun 24. pii: 10.1007/s10549-021-06306.
    PubMed         Abstract available
    
    
25. ADEMUYIWA FO, Chen I, Luo J, Rimawi MF, et al
    Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer.
    Breast Cancer Res Treat. 2021 Jun 26. pii: 10.1007/s10549-021-06307.
    PubMed         Abstract available
    
    
26. SHARMA U, Medina-Saenz K, Miller PC, Troness B, et al
    Heterotypic clustering of circulating tumor cells and circulating cancer-associated fibroblasts facilitates breast cancer metastasis.
    Breast Cancer Res Treat. 2021 Jul 3. pii: 10.1007/s10549-021-06299.
    PubMed         Abstract available
    
    
27. JACOBS DHM, Charaghvandi RK, Horeweg N, Maduro JH, et al
    Health-related quality of life of early-stage breast cancer patients after different radiotherapy regimens.
    Breast Cancer Res Treat. 2021 Jul 3. pii: 10.1007/s10549-021-06314.
    PubMed         Abstract available
    
    
28. MCGUINNESS JE, Altoe ML, Marone A, Franks LE, et al
    Diffuse optical tomography breast imaging measurements are modifiable with pre-surgical targeted and endocrine therapies among women with early stage breast cancer.
    Breast Cancer Res Treat. 2021 Jul 2. pii: 10.1007/s10549-021-06320.
    PubMed         Abstract available
    
    
29. CASTELO M, Brown Z, D'Abbondanza JA, Wasilewski NV, et al
    Psychological consequences of MRI-based screening among women with strong family histories of breast cancer.
    Breast Cancer Res Treat. 2021 Jul 2. pii: 10.1007/s10549-021-06300.
    PubMed         Abstract available
    
    
30. KEARNEY MR, McGuinness JE, Kalinsky K
    Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2- negative breast cancer.
    Breast Cancer Res Treat. 2021 Jul 2. pii: 10.1007/s10549-021-06291.
    PubMed         Abstract available
    
    
31. HASHIMOTO TAKIGAMI N, Kuniyoshi S, Miki Y, Tamaki K, et al
    Breast Cancer, Diabetes Mellitus and Glucagon-Like Peptide-1 Receptor Toward Exploring Their Possible Associations.
    Breast Cancer Res Treat. 2021 Jul 2. pii: 10.1007/s10549-021-06288.
    PubMed         Abstract available
    
    
32. REN M, Orozco A, Shao K, Albanez A, et al
    Germline variants in hereditary breast cancer genes are associated with early age at diagnosis and family history in Guatemalan breast cancer.
    Breast Cancer Res Treat. 2021 Jul 1. pii: 10.1007/s10549-021-06305.
    PubMed         Abstract available
    
    
33. ABUBAKAR M, Guo C, Koka H, Zhu B, et al
    Impact of breast cancer risk factors on clinically relevant prognostic biomarkers for primary breast cancer.
    Breast Cancer Res Treat. 2021 Jun 29. pii: 10.1007/s10549-021-06294.
    PubMed         Abstract available
    
    
34. JOHNSON JE, Strassle PD, de Oliveira GC, Agala CB, et al
    Suboptimal therapy following breast conserving surgery in triple-negative and HER2-positive breast cancer patients.
    Breast Cancer Res Treat. 2021 Jun 26. pii: 10.1007/s10549-021-06303.
    PubMed         Abstract available
    
    
35. FILIPE MD, Siesling S, Vriens MR, van Diest P, et al
    The association of socioeconomic status on treatment strategy in patients with stage I and II breast cancer in the Netherlands.
    Breast Cancer Res Treat. 2021 Jun 26. pii: 10.1007/s10549-021-06308.
    PubMed         Abstract available
    
    
36. LOPES CARDOZO JMN, Schmidt MK, van 't Veer LJ, Cardoso F, et al
    Combining method of detection and 70-gene signature for enhanced prognostication of breast cancer.
    Breast Cancer Res Treat. 2021 Jun 30. pii: 10.1007/s10549-021-06315.
    PubMed         Abstract available
    
    

    
    Breast J

37. MARQUES-ANTUNES J, Braga J, Santos T, Nora M, et al
    Basal cell carcinoma after radiation therapy in breast cancer.
    Breast J. 2021 Jun 26. doi: 10.1111/tbj.14266.
    PubMed        
    
    

    
    Cancer Epidemiol Biomarkers Prev

38. HINES RB, Johnson AM, Lee E, Erickson S, et al
    Trends in Breast Cancer Survival by Race-Ethnicity in Florida, 1990-2015.
    Cancer Epidemiol Biomarkers Prev. 2021;30:1408-1415.
    PubMed         Abstract available
    
    
39. FARHAT Z, Cadeau C, Eliassen AH, Freudenheim JL, et al
    Periodontal disease and breast cancer risk: Results from the Nurses' Health Study.
    Cancer Epidemiol Biomarkers Prev. 2021 Jun 29. pii: 1055-9965.EPI-21-0257.
    PubMed         Abstract available
    
    

    
    Cancer Res

40. HAN YJ, Zhang J, Lee JH, Mason JM, et al
    The BRCA1 Pseudogene Negatively Regulates Antitumor Responses through Inhibition of Innate Immune Defense Mechanisms.
    Cancer Res. 2021;81:1540-1551.
    PubMed         Abstract available
    
    
41. ZHOU Y, Jin X, Ma J, Ding D, et al
    HDAC5 Loss Impairs RB Repression of Pro-Oncogenic Genes and Confers CDK4/6 Inhibitor Resistance in Cancer.
    Cancer Res. 2021;81:1486-1499.
    PubMed         Abstract available
    
    
42. TERVONEN TA, Pant SM, Belitskin D, Englund JI, et al
    Oncogenic Ras Disrupts Epithelial Integrity by Activating the Transmembrane Serine Protease Hepsin.
    Cancer Res. 2021;81:1513-1527.
    PubMed         Abstract available
    
    

    
    Carcinogenesis

43. ZHOU B, Huang WH, Chen S, Chen W, et al
    GDF15 serves as a coactivator to enhance KISS-1 gene transcription through interacting with Sp1.
    Carcinogenesis. 2021;42:294-302.
    PubMed         Abstract available
    
    
44. ZHU P, Lu J, Zhi X, Zhou Y, et al
    tRNA-derived fragment tRF Lys-CTT-010 promotes triple-negative breast cancer progression by regulating glucose metabolism via G6PC.
    Carcinogenesis. 2021 Jul 3. pii: 6314212. doi: 10.1093.
    PubMed         Abstract available
    
    
45. SINGHAL J, Chikara S, Horne D, Awasthi S, et al
    Targeting RLIP with CRISPR/Cas9 controls tumor growth.
    Carcinogenesis. 2021;42:48-57.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

46. KOH SB, Ross K, Isakoff SJ, Melkonjan N, et al
    RASAL2 confers collateral MEK/EGFR dependency in chemoresistant triple-negative breast cancer.
    Clin Cancer Res. 2021 Jun 24. pii: 1078-0432.CCR-21-0714.
    PubMed         Abstract available
    
    

    
    Clin Exp Metastasis

47. KITZ J, Goodale D, Postenka C, Lowes LE, et al
    EMT-independent detection of circulating tumor cells in human blood samples and pre-clinical mouse models of metastasis.
    Clin Exp Metastasis. 2021;38:97-108.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

48. MARME F, Solbach C, Michel L, Schneeweiss A, et al
    Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy.
    Eur J Cancer. 2021;153:203-212.
    PubMed         Abstract available
    
    
49. MUELLER V, Wardley A, Paplomata E, Hamilton E, et al
    Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).
    Eur J Cancer. 2021;153:223-233.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

50. OFFERSEN BV, Poortmans P
    This house believes that all node positive breast cancer patients need post mastectomy radiation therapy.
    Eur J Surg Oncol. 2021 Jun 29. pii: S0748-7983(21)00592.
    PubMed        
    
    

    
    Gene

51. GYAN E, Owiredu WKBA, Ahenkorah-Fondjo L, Jackson AM, et al
    A review of the racial heterogeneity of breast cancer stem cells.
    Gene. 2021 Jun 28:145805. doi: 10.1016/j.gene.2021.145805.
    PubMed         Abstract available
    
    

    
    Int J Cancer

52. CHA C, Ahn SG, Kim D, Lee J, et al
    Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
    Int J Cancer. 2021 Jul 2. doi: 10.1002/ijc.33726.
    PubMed         Abstract available
    
    
53. DARLIX A, Hirtz C, Mollevi C, Ginestet N, et al
    Serum GFAP is a predictor of brain metastases in patients with metastatic breast cancer.
    Int J Cancer. 2021 Jul 1. doi: 10.1002/ijc.33724.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

54. SURA K, Chen PY
    Determining the Optimal Treatment of Locally Advanced Breast Cancer With Sequelae of Dermatomyositis.
    Int J Radiat Oncol Biol Phys. 2021;110:940-941.
    PubMed        
    
    
55. RODIN D, Strauss JB, R Bellon J
    "Standard" Fractionation for Breast Cancer is No Longer Standard.
    Int J Radiat Oncol Biol Phys. 2021;110:925-927.
    PubMed        
    
    
56. NAOUM GE, Taghian AG
    Regional Lymph Nodes Radiation and Breast Cancer Related Lymphedema: Where We Stand.
    Int J Radiat Oncol Biol Phys. 2021;110:1159-1160.
    PubMed        
    
    
57. PINKAWA M
    Spinal Cord Reirradiation:Balancing Benefit Against Risks.
    Int J Radiat Oncol Biol Phys. 2021;109:312-313.
    PubMed        
    
    
58. PASALIC D, Strom EA, Allen PK, Williamson TD, et al
    Proton Accelerated Partial Breast Irradiation: Clinical Outcomes at a Planned Interim Analysis of a Prospective Phase 2 Trial.
    Int J Radiat Oncol Biol Phys. 2021;109:441-448.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

59. LAMBERTINI M, Blondeaux E, Bruzzone M, Perachino M, et al
    Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis.
    J Clin Oncol. 2021 Jul 1:JCO2100535. doi: 10.1200/JCO.21.00535.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

60. CHOI E, Jun JK, Suh M, Jung KW, et al
    Effectiveness of the Korean National Cancer Screening Program in reducing breast cancer mortality.
    NPJ Breast Cancer. 2021;7:83.
    PubMed         Abstract available
    
    
61. PUGLISI F, Gerratana L, Lambertini M, Ceppi M, et al
    Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer.
    NPJ Breast Cancer. 2021;7:82.
    PubMed         Abstract available
    
    
62. PARKES EE, Humphries MP, Gilmore E, Sidi FA, et al
    The clinical and molecular significance associated with STING signaling in breast cancer.
    NPJ Breast Cancer. 2021;7:81.
    PubMed         Abstract available
    
    
63. WORTMAN JC, He TF, Solomon S, Zhang RZ, et al
    Spatial distribution of B cells and lymphocyte clusters as a predictor of triple-negative breast cancer outcome.
    NPJ Breast Cancer. 2021;7:84.
    PubMed         Abstract available
    
    

    
    Oncogene

64. QIU Y, Yang Y, Yang R, Liu C, et al
    Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer.
    Oncogene. 2021 Jun 25. pii: 10.1038/s41388-021-01896.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

65. ERDEM C, Lee AV, Taylor DL, Lezon TR, et al
    Inhibition of RPS6K reveals context-dependent Akt activity in luminal breast cancer cells.
    PLoS Comput Biol. 2021;17:e1009125.
    PubMed         Abstract available
    
    

    
    Radiology

66. OZUTEMIZ C, Krystosek LA, Church AL, Chauhan A, et al
    Lymphadenopathy in COVID-19 Vaccine Recipients: Diagnostic Dilemma in Oncology Patients.
    Radiology. 2021 Feb 24:210275. doi: 10.1148/radiol.2021210275.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: